Schmitz Joy M, Stotts Angela L, Vujanovic Anka A, Weaver Michael F, Yoon Jin H, Vincent Jessica, Green Charles E
Department of Psychiatry & Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, United States.
Department of Psychiatry & Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, United States; Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, United States.
Contemp Clin Trials. 2018 Feb;65:109-115. doi: 10.1016/j.cct.2017.12.015. Epub 2017 Dec 26.
Drug addiction is a chronic, devastating, but treatable disorder. A core principle of drug addiction treatment states that no single treatment is appropriate for everyone (NIDA, 2012); treatments need to adjust based on patient characteristics and response in order to be maximally effective. For cocaine use disorders (CUD), specifically, the most potent intervention currently available for initiating abstinence is behavior therapy using contingency management (CM) procedures, with early cessation being a robust predictor of future abstinence. This raises two key questions for treatment development research: First, can we significantly improve initial CM response rates with targeted adjunctive interventions? Second, for individuals who fail to achieve initial abstinence with CM, is pharmacotherapy an effective augmentation strategy? This paper describes how a sequential, multiple assignment, randomized trial (SMART) design has advantages over a fixed-intervention approach when it comes to collecting data needed to answer both questions. The first aim will examine whether Acceptance and Commitment Therapy (ACT) in combination with CM increases initial abstinence response rates (i.e., 2 consecutive weeks of cocaine-negative urine screens). The second aim will examine whether ACT+CM in combination with modafinil promotes abstinence achievement in initial non-responders. Results are expected to inform how we tailor treatment of CUD to maximize outcomes.
药物成瘾是一种慢性、具有破坏性但可治疗的疾病。药物成瘾治疗的一个核心原则是,没有一种单一的治疗方法适用于所有人(美国国家药物滥用研究所,2012年);治疗方法需要根据患者的特征和反应进行调整,以达到最大疗效。具体而言,对于可卡因使用障碍(CUD),目前可用于促使戒断的最有效干预措施是采用应急管理(CM)程序的行为疗法,早期戒断是未来保持戒断状态的有力预测指标。这为治疗开发研究提出了两个关键问题:第一,我们能否通过有针对性的辅助干预措施显著提高初始CM反应率?第二,对于那些未能通过CM实现初始戒断的个体,药物治疗是否是一种有效的强化策略?本文描述了在收集回答这两个问题所需的数据方面,序贯多重分配随机试验(SMART)设计相对于固定干预方法具有哪些优势。第一个目标将研究接纳与承诺疗法(ACT)与CM相结合是否会提高初始戒断反应率(即连续2周可卡因尿液筛查呈阴性)。第二个目标将研究ACT+CM与莫达非尼相结合是否能促进初始无反应者实现戒断。预计研究结果将为我们如何量身定制CUD治疗方案以实现最佳治疗效果提供参考。